This is a randomized single-blinded clinical trial. Were included 60 women up to 65 years of age with established menopause (at least 12 months since the last menstrual period or a bilateral oophorectomy) who presented one or more of the clinical signs and symptoms of GSM, and with vaginal pH ≥ 5 and predominance of basal epithelial cells cytology. Were excluded: women in use of pacemaker, hormone replacement therapy up to six months prior to the study, pregnant women, hemophiliacs, patients using vasodilators and/or anticoagulants, women with cognitive impairment or psychiatric illness, chronic degenerative neurological diseases, with metal prosthesis in the pelvic region, with diagnosis of vaginal infections, and those who didn’t sign the Free and Informed Consent Form (FICF). Once accepting informed consent, the participants were asked to complete self-administered questionnaires: Sociocultural Questionnaire (Table 1), Female Sexual Function Index (FSFI), Sexual Quotient – Female Version (SQ-F), Female Genital Self- Image Scale-7 (FGSIS-7), and Visual Analogic Scale (VAS). A secretary, who is not part of the study, carried out the randomization using a random table generated on the website www.random.org and ensured that the allocation concealment of participants into two groups: Intervention Group (IG) and Kinesiotherapy Group (KG). In the IG, non-ablative radiofrequency (RF) with a Capenergy brand device, model C500 (Barcelona, Spain), was used keeping the temperature in 40°C. When the temperature was reached, the active electrode was maintained for 2 minutes on the anterior vaginal wall and 2 minutes on the posterior vaginal wall, totalizing 4 minutes. Immediately after the application of NARF, the physiotherapist performed a pelvic floor muscle training with the patient. The participants were then instructed to perform the same exercises at home, twice a day. For the KG the treatment protocol was the same, however, in this group, the NARF was turned off and warmed gel was applied. The treatment consisted of five NARF sessions, once a week. The entire evaluation protocol was applied before and immediately after the five treatment sessions, being carried out by the same initial evaluators. To create the database, descriptive and analytical analysis, the Statistical Package for Social Sciences (SPSS) software, version 22.0 for MAC, was used. Paired Student's t was used for paired analyses. The independent Student's t test was used to compare independent data. The significance level adopted was 5%. The sample calculation was performed using the WINPEPI calculator. The data to evaluate the clinical efficacy of radiofrequency in the treatment of vulvovaginal atrophy were extracted from the study by Yaralizadeh[3].